Simultaneous and Rapid Determination of Six Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Using HPLC-MS/MS

Table 4

Extraction recovery and matrix effect of six analytes (%) (n = 3).

Analytes	Nominal concentration (ng/mL)	Extraction recovery		Matrix effect
		Mean (%) ± SD	RSD (%)	Mean (%) ± SD	RSD (%)
Gefitinib	20	91.18 ± 3.49	3.08	114.09 ± 7.4	2.56
	100	80.75 ± 3.34		113.83 ± 8.88
	500	97.18 ± 1.13		108.98 ± 11.45
Icotinib	100	81.41 ± 1.33	3.11	107.58 ± 4.28	3.49
	500	93.89 ± 3.91		100.91 ± 2.91
	2000	96.02 ± 1.62		101.85 ± 5.85
Erlotinib	100	85.24 ± 3.33	3.00	108.67 ± 8.22	5.49
	500	90.10 ± 1.8		101.26 ± 2.47
	2000	85.85 ± 1.99		97.63 ± 5.90
Crizotinib	20	76.66 ± 6.33	2.71	109.91 ± 12.21	5.31
	100	77.75 ± 5.15		100.98 ± 7.88
	500	82.10 ± 3.87		96.83 ± 11.76
Osimertinib	20	82.25 ± 7.63	2.92	100.58 ± 4.94	2.97
	100	90.53 ± 2.48		102.72 ± 5.27
	500	81.76 ± 4.03		96.85 ± 10.60
Afatinib	10	85.20 ± 1.38	3.12	102.56 ± 17.39	2.91
	50	90.55 ± 8.06		108.45 ± 15.34
	200	95.69 ± 8.61		107.08 ± 9.03

RSD was calculated using the IS-normalized matrix and recovery factors.